Close
Found 0 results for your search. Showing 0 to 0.
No results could be found for your search.
x Close Search
Close

Publications

Human papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007-2016.
GALLAGHER, KE; HOWARD, N; Kabakama, S; MOUNIER-JACK, S; BURCHETT, HE D; LaMontagne, DS; WATSON-JONES, D;
2017
Papillomavirus research (Amsterdam, Netherlands), (2017).4, 10.1016/j.pvr.2017.09.001.
Kinetics of antibodies against pneumococcal proteins and their relationship to nasopharyngeal carriage in the first two months of life.
Mendy, AL; AGBLA, SC; ODUTOLA, AA; ANTONIO, M; GREENWOOD, BM; SUTHERLAND, JS; Ota, MO C;
2017
PloS one, (2017).12 10 10.1371/journal.pone.0185824.
Cervical Cancer Prevention Through HPV Vaccination in Low- and Middle-Income Countries in Asia.
Toh, ZQ; Licciardi, PV; Russell, FM; Garland, SM; Batmunkh, T; MULHOLLAND, EK;
2017
Asian Pac J Cancer Prev, (2017).18 9 10.22034/APJCP.2017.18.9.2339.
What Have We Learnt about BCG Vaccination in the Last 20 Years?.
DOCKRELL, HM; SMITH, SG;
2017
Frontiers in immunology, (2017).8 SEP 10.3389/fimmu.2017.01134.
Capturing Budget Impact Considerations Within Economic Evaluations: A Systematic Review of Economic Evaluations of Rotavirus Vaccine in Low- and Middle-Income Countries and a Proposed Assessment Framework.
Carvalho, N; JIT, M; Cox, S; Yoong, J; Hutubessy, RC W;
2017
PharmacoEconomics, (2017).36 1 10.1007/s40273-017-0569-2.
Prevalence of signs of trachoma, ocular Chlamydia trachomatis infection and antibodies to Pgp3 in residents of Kiritimati Island, Kiribati.
Cama, A; Müller, A; Taoaba, R; BUTCHER, RM R; Itibita, I; MIGCHELSEN, SJ; Kiauea, T; PICKERING, H; Willis, R; ROBERTS, CH; Bakhtiari, A; Le Mesurier, RT; ALEXANDER, ND E; Martin, DL; Tekeraoi, R; Solomon, AW; Global Trachoma Mapping Project,;
2017
PLoS neglected tropical diseases, (2017).11 9 10.1371/journal.pntd.0005863.
Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules.
CLARK, A; Tate, J; Parashar, U; JIT, M; Hasso-Agopsowicz, M; Henschke, N; Lopman, B; VAN ZANDVOORT, K; Pecenka, C; FINE, P; SANDERSON, C;
2017
The Lancet Global Health, (2017).7 11 10.1016/S2214-109X(19)30412-7.
Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness.
Wichmann, O; Vannice, K; Asturias, EJ; De Albuquerque Luna, EJ; Longini, I; Lopez, AL; SMITH, PG; Tissera, H; Yoon, I-K; Hombach, J;
2017
Vaccine, (2017).35 42 10.1016/j.vaccine.2017.08.066.
Data and product needs for influenza immunization programs in low- and middle-income countries: Rationale and main conclusions of the WHO preferred product characteristics for next-generation influenza vaccines.
Neuzil, KM; Bresee, JS; De la Hoz, F; Johansen, K; Karron, RA; Krishnan, A; Madhi, SA; MANGTANI, P; Spiro, DJ; Ortiz, JR; WHO Preferred Product Characteristics for Next-Gen,;
2017
Vaccine, (2017).35 43 10.1016/j.vaccine.2017.08.088.
The duration of protection of school-aged BCG vaccination in England: a population-based case-control study.
MANGTANI, P; NGUIPDOP-DJOMO, P; KEOGH, RH; Sterne, JA C; Abubakar, I; SMITH, PG; FINE, PE M; VYNNYCKY, E; Watson, JM; Elliman, D; Lipman, M; RODRIGUES, LC;
2017
International journal of epidemiology, (2017).47 1 10.1093/ije/dyx141.